KR-33028

• Description :

  KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke[1][2].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Na+/H+ Exchanger (NHE)

• Related Pathways :

  Apoptosis; Membrane Transporter/Ion Channel

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Cardiovascular Disease

• Smiles :

  O=C(C1=CC2=C(C#N)C=CC=C2S1)NC(N)=N

• Molecular Formula :

  C11H8N4OS

• Molecular Weight :

  244.27

• References & Citations :

  [1]Amith SR, et al. KR-33028, a potent inhibitor of the Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells. Biochem Pharmacol. 2016 Oct 15;118:31-39.|[2]Jung YS, et al. Pharmacological profile of KR-33028, a highly selective inhibitor of Na+/H+ exchanger. Eur J Pharmacol. 2006 Mar 27;535 (1-3) :220-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [861218-37-3]